Table 1.
Clinical characteristics of patients who underwent pancreatectomy
| Total (N = 109) | PD (N = 73) | DP (N = 36) | P | |
|---|---|---|---|---|
| Age, y | 66.1 ± 0.87 | 66.9 ± 1.0 | 64.5 ± 1.6 | NS |
| Male, n (%) | 57 (53.8%) | 43 (58.9%) | 14 (38.9%) | < .05 |
| Height, cm | 159.9 ± 0.87 | 160.5 ± 1.1 | 158.8 ± 1.6 | NS |
| Body weight, kg | 57.6 ± 1.2 | 58.9 ± 1.5 | 54.6 ± 2.0 | NS |
| BMI, kg/m2 | 22.4 ± 0.36 | 22.7 ± 0.43 | 21.6 ± 0.66 | NS |
| Histology of pancreas lesion | – | – | – | NS |
| Malignant, n (%) | 72 (66.1%) | 52 (71.2%) | 20 (55.6%) | |
| Benign, n (%) | 37 (33.9%) | 21 (28.8%) | 16 (44.4%) | |
| HbA1c, mmol/mol | 40.3 ± 0.46 | 40.1 ± 0.60 | 40.8 ± 0.69 | NS |
| HbA1c, % | 5.84 ± 0.04 | 5.82 ± 0.05 | 5.88 ± 0.06 | NS |
| Fasting blood glucose, mmol/L | 5.10 ± 0.05 | 5.16 ± 0.06 | 4.97 ± 0.09 | NS |
| Fasting insulin, µIU/mL × min | 6.12 ± 0.31 | 6.19 ± 0.39 | 5.99 ± 0.54 | NS |
| Fasting C-peptide, nmol/L | 0.60 ± 0.02 | 0.62 ± 0.03 | 0.56 ± 0.04 | NS |
| HOMA-IR | 1.41 ± 0.08 | 1.44 ± 0.10 | 1.34 ± 0.13 | NS |
| BT-PABA test, %a | 58.5 ± 1.1 | 57.2 ± 1.5 | 61.2 ± 2.0 | NS |
| Administration of pancreatic enzyme drug, n (%)b | 26 (23.9%) | 18 (24.7%) | 8 (22.2%) | NS |
| Dosage of pancreatic enzyme drug, mg/db | 1453.8 ± 87.6 | 1400.0 ± 108.5 | 1 575.0 ± 147.3 | NS |
| Intraoperative blood loss, mL | 916.4 ± 120.8 | 1182.4 ± 167.4 | 376.9 ± 83.5 | < .001 |
| Intraoperative blood transfusion, mL | 195.2 ± 45.2 | 237.8 ± 62.0 | 108.9 ± 52.7 | NS |
Data are presented as mean ± SEM. Categorical variables were compared using the chi-square test, and continuous variables using unpaired t tests between PD and DP. Statistical significance was defined as P less than 0.05.
Abbreviations: BMI, body mass index; BT-PABA, N-benzoyl-L-tyrosyl-p-aminobenzoic acid; DP, distal pancreatectomy; HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; NS, not significant; PD, pancreaticoduodenectomy.
a The BT-PABA test was performed in 89 patients (60 with PD and 29 with DP).
b The pancreatic enzyme drug was pancrelipase (Mylan EPD G.K.).